3.1.8. urological malignancy renal transplantation. following section limited synopsis three systematic reviews conducted eau renal transplantation panel. 3.1.8.1. malignancy prior renal transplantation 3.1.8.1.1. recipient standard procedure transplant candidates includes systematic screening presence active/latent cancer past history cancer. candidates previous history urological cancer, challenging decide patients suitable transplantation long waiting period prior transplantation be. date, waiting period primarily based cincinnati registry, takes account type tumour time treatment kidney transplantation. however, cincinnati registry potential drawbacks consider epidemiology tumours diagnostic therapeutic procedures/tests changed time prognostic tools improved. additionally, treatment staging disease defined. according recent systematic review risk tumour recurrence similar transplantation (n=786) dialysis (n=1,733) populations renal cell carcinoma (rcc) prostate cancer (pca). especially true low grade/stage pca, risk recurrence low consistent nomograms . low stage/grade rcc recurrence rate significant dialysis renal transplantation; however, recurrences actually contralateral rcc impact patient graft survival . testicular cancer low risk recurrence case reports highlighted possibility late recurrence even stage tumours . urothelial carcinoma, studies mainly related upper urinary tract carcinomas context aristolochic acid nephropathy rate synchronous bilateral tumour 10-16% rate contralateral recurrence 31-39% . findings imply kidney transplant candidate history appropriately treated low stage/grade pca (psa ≤ 10, gleason score ≤ 6 t1/t2a) low grade t1 rcc could listed renal transplantation without additional delay compared cancer-free patient. however, level evidence low, studies needed standardise waiting periods renal transplantation. summary evidencelerenal cell carcinomathe recurrence rates transplanted vs. dialysed patients <1, 1–5, > 5 years 0–8% vs. 0%, 0–27% vs. 0–9% 0–41% vs. 0–48%, respectively.2boverall five year survival rates transplantation vs dialysed patients 80–100% vs. 76–100%, respectively.prostate cancerthe recurrence rates transplantation patients <1 > 5 years 0–9% 4–20%, respectively.2boverall, 1–5 year survival rates transplantation patients ranged 62% 100%. recommendationstrength ratinglist renal transplantation patients history appropriately treated low stage/grade renal cell carcinoma prostate cancer without additional delay.weak 3.1.8.1.2. potential donor kidney general population, rcc constitutes 3% malignancies, incidence highest patients aged > 60 years. current increasing age donors may lead higher number incidental rccs found donor kidneys could theoretically decrease number kidneys suitable transplantation. main surgical approach kidneys ex vivo tumour excision back-table oncological margin, frozen section biopsy, bench surgery renorraphy, finally transplantation conventional fashion . systematic review assessed effectiveness harms using kidneys small renal tumours, deceased living donors, source renal transplantation reported five year overall graft survival rates 92% 95.6%, respectively . tumour excision performed ex-vivo cases except two (107/109 patients), vast majority excised tumours rccs (88/109 patients), clear-cell subtype common . systematic review, although low-level evidence, suggested kidneys small renal masses acceptable source renal transplantation compromise oncological outcomes similar functional outcomes donor kidneys. summary evidenceletumour excision performed ex-vivo cases except two (107/109 patients).2boverall survival rates one, three five years 97.7%, 95.4%, 92%, respectively.mean graft survival rates one, three five years 99.2%, 95%, 95.6%, respectively. recommendationstrength ratingdo discard kidney potential transplantation basis small renal mass alone.weak 3.1.8.2. malignancy renal transplantation cancer development kidney transplant become major problem one main causes death population. urological cancers, increased incidence kidney transplantation partly due increasing age recipients prolonged survival transplantation. treatment localised pca following kidney transplantation challenging due presence kidney graft pelvic cavity close prostate. two systematic reviews reported oncological outcomes following pca treatment kidney transplant recipients comparable non-transplanted population surgery (radical prostatectomy), carried tertiary high-volume referral centres treatment choice 75 85% patients . marra et al., reported cancer-specific survival rates 96.8% surgery, 88.2% radiotherapy androgen deprivation therapy 100% brachytherapy mean follow-up 24 months . hevia et al., reported five year cancer-specific survival 97.5% surgery, 87.5% external beam radiation 94.4% brachytherapy . summary evidencelesurgery (radical prostatectomy) frequently performed treatment localised pca kidney transplant.2boverall oncological outcomes following pca treatment kidney transplant recipients comparable non-transplanted population.2b recommendationsstrength ratingbe aware presence kidney transplant pelvis possibility subsequent transplants planning treatment prostate cancer.strongrefer kidney transplant patients prostate cancer integrated transplant urology centre.strong